

## عنوان مقاله:

Theoretical study of the tautomerization of Carmustine in a biological media as an anti-cancer drug

## محل انتشار:

فصلنامه علوم و فناوری ذرات، دوره 7، شماره 1 (سال: 1400)

تعداد صفحات اصل مقاله: 7

## نویسندگان:

.Mahnoush Momeni Landi - *Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran*

.Sayed Ali Ahmadi - *Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran*

.Mohammad Reza Akhgar - *Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran*

.Dadkhoda Ghazanfari - *Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran*

## خلاصه مقاله:

Tautomers can be defined as isomers of single molecules existing in solutions or cells. Tautomers have the ability to interchange due to numerous spontaneous arrangements of chemical bonds, unlike chirality, whose molecules represent mirror images of enantiomers of one another. Tautomerization of the carmustine mechanism as a potential anti-cancer medication was examined using the DFT method. Two conformational tautomers were identified in the structure of carmustine, and the structure of both tautomers was shown to consider the contribution of atom changes to carmustine conformation. It was possible to obtain the relative energies B<sup>3</sup>LYP/6-311G++ (d,p), Aug-cc-pVDZ, and 6-311++g(2d,2p) basis sets. Calculations of the highest occupied molecular orbital (HOMO), the lowest unoccupied orbital (LUMO), and bandgap energies of structures were performed while also obtaining the electronics parameters, electrophilicity, electronegativity, softness, and hardness in order to determine the compounds' reactivity within the biological medium. Based on the results, the carmustine structure and both tautomer conformations showed stability, but T<sub>1</sub> had greater stability than T<sub>2</sub>.

## کلمات کلیدی:

DFT, carmustine, Tautomer, Electronic parameter, Anti-cancer

## لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/1534204>

